Forgot Password?
Return to Course Listing

CME: Alzheimer Disease and Its Complications: Best Practices, Emerging Therapies, and Barriers to Care


AN ACCREDITED UP-TO-DATE VERSION OF THIS TOPIC CAN BE FOUND AT: Contemporary challenges and updates and in the diagnosis and management of Alzheimer’s disease – from early disease onward

Activity Description / Statement of Need:

In this online, self-learning activity:

Alzheimer Disease (AD) is a degenerative disease that most commonly affects the elderly, although it is occasionally detected as early as middle age. AD accounts for over half of all diagnosed dementia, the prevalence of which is increasing. Once there is a diagnosis of probable AD, one must determine which pharmacotherapy, if any, is most appropriate for treatment of the patient. The literature suggests that gaps in care on the part of healthcare professionals exist. While some physicians continue to use the antiquated, nonspecific term “senile dementia” as a descriptive diagnosis of AD, perhaps suggesting a lack of understanding of the gravity of the disease state or its associated pathophysiology, other report feeling uncertain at times about now to best diagnosis of the disease, particularly in its very early stages. Moreover, a number of different practice guidelines have been updated recently, and HCPs are often unable to keep up with the publishing of literature and evolution of clinical practice.

Target Audience:

Healthcare professionals specializing in: neurology, gerontology, internal medicine, palliative care, or those who otherwise commonly care for patients with AD or who frequently encounter them or their caregivers in practice.

This program is supported by an educational grant from Eli Lilly and Company.

Release Date: July 09, 2020 -- Expiration Date: July 09, 2022

Faculty: Mario Mendez, MD


Introduction, Disclosures

Epidemiology of and risk factors for AD

  • Statistics
  • Gender and racial disparities
  • Age
  • Genetics
  • Comorbid diseases (diabetes, vascular disease)
  • Modifiable risk factors (smoking)

Symptomology and diagnosis of AD

  • Onset and memory impairment
  • Cognitive decline (language, motor function, poor insight, neuropsychiatric manifestations)
  • Pathology and changes in brain
  • Imaging studies
  • Mini Mental State Examination
  • Diagnostic challenges in AD

Treatment in patients with AD

  • Therapies: Pharmacologic vs. non- (behavioral, rehabilitation), first-line and beyond
  • Emerging strategies, trends, and therapies in recent years: Aducanumab, AMG 502 / CNP520, ABBV-8E12, BAN2401, E2609, LY3002813, LY3303560
  • Complications and barriers to optimal care in patients with AD
      • The range of cognitive and behavioral complications
      • Safety first: pitfalls in antipsychotic use
      • Adherence to therapy and modifiable risk factors
  • Best practice: Putting it all together
  • Patient cases

Summary, conclusions, and best practice recap

Learning Objectives

By the end of the session the participant will be able to:

  • Describe what is presently known about the pathophysiology of AD.
  • Describe the challenges associated with diagnosis and treatment of ADDiscuss the neuropathophysiology of AD and how it relates to presently available AD treatments mechanisms.
  • Identify the present treatment options currently available for management of AD and apply them to patient cases using evidence-based medicine.
  • Describe emerging drug therapies in the treatment of AD.
  • Evaluate a treatment plan for a specific patient based on degree of AD to optimize safety and efficacy, suggesting modifications for improvement.


ACCME Activity # 201806121


Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

Faculty Disclosure: Mario F. Mendez, MD, PhD, Director, Behavioral Neurology Program, Professor Neurology and Psychiatry, David Geffen School of Medicine at UCLA,has no relevant conflicts of interest to disclose.

Disclosures of Educational Planners: Charles Turck, PharmDBCPS, BCCCP, CEO of ScientiaCME, has no relevant conflicts of interest to disclose.

Commercial Support Disclosure: This program is supported by an educational grant from Eli Lilly and Company.


  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

Additional Courses That Are Related To This Activity

Transthyretin amyloidosis (ATTR) and its complications: Optimizing management strategies

Parkinson's disease: Optimizing pharmacotherapeutic management strategies and addressing clinical challenges

Chronic inflammatory demyelinating polyneuropathy (CIDP): Optimizing pharmacotherapeutic management strategies

Transthyretin amyloidosis (ATTR) and its complications: Optimizing management strategies